Back

Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study

de Prost, N.; Audureau, E.; Guillon, A.; Handala, L.; Preau, S.; Guigon, A.; Uhel, F.; Le Hingrat, Q.; Delamaire, F.; Grolhier, C.; Tamion, F.; Moisan, A.; Darreau, C.; Thomin, J.; Contou, D.; Henry, A.; Daix, T.; Hantz, S.; Saccheri, C.; Giordanengo, V.; Pham, T.; Chaghouri, A.; Bay, P.; Pawlotsky, J.; Fourati, S.

2024-03-13 intensive care and critical care medicine
10.1101/2024.03.11.24304075 medRxiv
Show abstract

A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.